A research company at University College Dublin will receive €650,000 in venture capital to fund its research into manufacturing pharmaceuticals with reduced side effects.
Celtic Catalysts was founded by Dr Brian Kelly and Dr Declan Gilheany. Its research focuses on technology for use in the biotechnology/life sciences industries.
The investment is being provided by 4th level Ventures, a €20 million dedicated to supporting high-potential start-ups, and Enterprise Ireland.
Celtic Catalysts plans to use the funding to commercialise its technology. The firm is based at the university's Innovation and Technology Centre, NovaUCD.